Objective: Disrupted sleep is common in pediatric cancer, which is associated with psychological distress and may impact neural recovery. Information regarding sleep during pediatric brain tumor treatment is limited. This study aimed to describe objective sleep-wake patterns and examine the sleep-mood relation in youth hospitalized for intensive chemotherapy and stem cell rescue.
life. 10 Youth with brain tumors, including medulloblastoma, are particularly vulnerable to these disruptions and report poorer quality of life than peers (both healthy and with non-CNS cancers). 2 Cancer survivors report greater psychological distress and depressive symptoms than siblings or demographically matched controls, and those treated for CNS tumors are particularly at risk. [11] [12] [13] This vulnerability may be compounded by poorer sleep quality and associated emotion dysregulation. 14 Healthy sleep is essential to memory consolidation, attention, executive function, and emotion regulation. 8, 15, 16 Patients with medulloblastoma are vulnerable to deficits in these areas; thus, it is important to elucidate what additional role sleep may play in daytime functioning. Healthy children with poor sleep are 6.9 times more likely to have comorbid anxiety or depression than those without sleep problems. 17 Emerging evidence suggests that sleep disturbances predate depression, after controlling for demographics and baseline depression. [18] [19] [20] Few studies examine objectively measured sleep in relation to mood outside of cross-sectional studies of youth with depression. [21] [22] [23] Studies in juvenile arthritis and sickle cell disease have utilized subjective measures of sleep quality and only focused on interactions between sleep quality and mood in relation to daily pain. 24, 25 There is scant research investigating mood in pediatric brain tumors during active treatment when the disease process, surgery, CNS radiation, hospitalizations, and decreased opportunities for social interactions may increase risk for poorer mood. No previous work has examined sleep and mood in pediatric patients with brain tumors.
Previous studies in pediatric oncology have focused on sleep among inpatient pediatric leukemia and solid tumors. 26, 27 Youth hospitalized for cancer treatment have poorer sleep efficiency than peers who are healthy, chronically ill, and hospitalized for noncancer illnesses. 26 Up to 40 nightly awakenings occur in pediatric oncology inpatients (compared with 4-6 nocturnal arousals in healthy children 28 ), and the longest sleep period for most patients is 1 to 2 hours, in comparison with healthy children who typically have brief arousals with return to sleep rather than complete awakenings. [26] [27] [28] Poor sleep may negatively impact daytime functioning including mood and be associated with maladaptive strategies such as daytime napping to compensate for poor nighttime sleep. Changes in sleep can persist following discharge, which can result in daytime dysfunction such as depressive symptoms. 29, 30 Patients with medulloblastoma may have increased vulnerability to sleep and daytime impairments, but the group is understudied compared with other pediatric cancers. As treatment requires frequent night awakenings, it was hypothesized that this sleep disruption may result in daytime mood disturbance. Therefore, it is important to investigate potential treatment targets to maximize patient outcomes.
Our goal was to describe mood disturbance and objective sleep-wake patterns during inpatient treatment for medulloblastoma and to examine the sleep-mood relationship after controlling for demographic and clinical characteristics.
2 | METHODS The primary intervention outcome found no group differences in brain tumor site, risk, presence of VP shunt, gender, or age. The high-risk disease group had shorter sleep duration and greater wake after sleep onset. 31 The treatment difference between average-and high-risk patients was the radiation dose, which occurred prior to this study.
| Participants and procedures

| Measures
| Wrist actigraphy
The Micro-mini motionlogger (Ambulatory Monitoring Inc, Ardsley, New York) provided an objective estimate of sleep-wake patterns.
The wristwatch-style device contains a biaxial piezoelectric sensor with an epoch length of 60 seconds. Families were instructed to press the event marker when attempting sleep and upon awakening. The system's software utilized Sadeh's algorithm, an approach validated against polysomnography in children. 32 Patients wore actigraphs throughout their hospitalization (up to 5 days), with most being 4 days.
| Mood disturbance
The Behavioral, Affective, and Somatic Experiences Scale Revised (BASES, revised) was originally designed for nurses to complete, has been adapted for self-and parent-report, and was validated for measuring short-term functioning in children hospitalized for intensive therapy. 33, 34 The revised BASES includes 5 subscales, with the Mood Disturbance subscale (7 items) used in this study. Patients ≥5 years of age and parents rated the child's experiences on a 5-point scale on the day of admission (day 0), day 2 or 3, and the evening before discharge, with recall periods of 1 day and consistent with the intended use. 34 Daily mood was computed by summing the 7 items for self-report (range = 7 to 35) or 8 items for parent-report (range = 8 to 40), with higher scores indicating greater mood disturbance. For those missing one item, the average of the answered items of the same individual was imputed for the missing item. This approach may be used for a small proportion of missing data, as has been conducted with the Brief Symptom Inventory and Neurocognitive Questionnaire, 35, 36 and missing data in this sample represented 5% to 7% for the parent and child BASES (respectively). Mood data for a given day were excluded if most items were missing. The BASES is intended to be sensitive to change 33, 34 and has been found to have good internal consistency (α = 0.82-0.86) for the mood disturbance subscale. 34 
| Data analysis
Descriptive statistics were estimated for participant characteristics, Descriptive statistics were stratified by age groups (ie, ≤12 and ≥13 years) most consistently described across national sleep and health organizations in terms of recommendations for age-based sleep needs. 37 Age was included as a covariate in regressions rather than stratifying by age because of the study sample size. The standard deviation across all patients and all nights was high (Table 2) , suggesting large between-subjects variability in nocturnal 
| Objective sleep
| Mood
Summary statistics are displayed in Table 2 for self-reported analysis examining mood patterns over the hospitalization, there were no significant differences in sleep between those with stable, worsened, or improved parent-reported mood (ie, on day 2 versus day of admission, P > .05).
| CONCLUSIONS
This study examined objective sleep estimates and subjective mood disturbance in youth with medulloblastoma who were hospitalized for high-dose chemotherapy and hematopoietic cell rescue. Most studies in pediatric brain tumors have focused on survivors, subjective sleep, and/or those referred to an outpatient clinic for sleep or hypersomnia complaints. 1, 2, 38, 39 There is no known research examining the relation between mood and objectively measured sleep in youth with chronic illness, and there is a paucity of information on objective sleep estimates during inpatient treatment for pediatric medulloblastoma.
Results showed that average nocturnal sleep duration fell well below the recommendations for optimal health in children (9 to 12 h) and adolescents (8 to 10 h) 37 and that sleep was highly fragmented. In contrast to previous studies finding that healthy children spend 85% to 95% of their time in bed sleeping, 40 our inpatients with medulloblastoma spent an average of 71% of their time in bed sleeping. Compared with previous studies of youth hospitalized for ALL 41 and solid tumors or acute myeloid leukemia, 27 our participants exhibited qualitatively more wake after sleep onset minutes and average number of nocturnal awakenings, 27,41 poorer sleep efficiency, 41 and lower nocturnal sleep duration. 27, 41 Findings can reflect the multitude of factors that may impact sleep during hospitalization for cancer treatment, including extrinsic (eg, noise from room entries/exits for patient monitoring or infusion pumps) and intrinsic (eg, chemotherapy and medication effects, physical discomfort, and CNS disease effects) sources of sleep disruption. The differences from previous research 27,41 may reflect greater vulnerability for poor sleep and daytime fatigue in medulloblastoma patients admitted for high-intensity chemotherapy compared with other previously studied pediatric cancers. [1] [2] [3] 5 In particular, treatment included high-dose chemotherapy requiring frequent monitoring and need to awaken patients multiple times at night to urinate to minimize chemotherapy-related nephrotoxicity, which placed them at greater risk of extrinsic impact on sleep than those with 
| Study limitations
Despite the important study contributions, there are several limitations.
Because of our small sample size, the analyses were not stratified by age group. However, a descriptive of all outcome measures by age is provided in Table 2 . An additional limitation was this study functioning as part of a larger study powered to address intervention aims rather than these exploratory aims for mood and sleep. Our sample consisted primarily of Caucasian youth. Although this may reflect the greater incidence of pediatric brain tumors among non-Hispanic Whites, 44 we cannot generalize results to those from other racial/ethnic backgrounds also affected by brain tumors. We were unable to examine the daily mood-sleep rela- and sleep disordered breathing, 38, 39 but it is unclear that the degree to which these problems present during active treatment. Given the impact of sleepiness and sleep-disordered breathing on cognitive functioning, sleep-wake patterns, and psychosocial functioning, 45, 46 it is important to investigate the presence and role of these factors across treatment. 
| Clinical implications
